{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.09","value":"-4.6"},{"groupId":"OG001","spread":"12.29","value":"-4.4"}]}],"title":"Physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.92","value":"-6.2"},{"groupId":"OG001","spread":"17.84","value":"-5.6"}]}],"title":"Role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.12","value":"0.5"},{"groupId":"OG001","spread":"13.23","value":"-0.5"}]}],"title":"Emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.77","value":"-3.7"},{"groupId":"OG001","spread":"16.37","value":"-3.8"}]}],"title":"Cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.31","value":"-2.7"},{"groupId":"OG001","spread":"18.18","value":"-4.0"}]}],"title":"Social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.46","value":"6.1"},{"groupId":"OG001","spread":"18.40","value":"7.0"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.12","value":"0.2"},{"groupId":"OG001","spread":"6.02","value":"0.8"}]}],"title":"Nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.19","value":"1.7"},{"groupId":"OG001","spread":"21.96","value":"4.0"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.16","value":"5.3"},{"groupId":"OG001","spread":"20.25","value":"7.9"}]}],"title":"Dyspnoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.88","value":"4.8"},{"groupId":"OG001","spread":"21.82","value":"4.8"}]}],"title":"Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.82","value":"-0.6"},{"groupId":"OG001","spread":"14.86","value":"-0.6"}]}],"title":"Appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.26","value":"1.4"},{"groupId":"OG001","spread":"18.88","value":"3.5"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.70","value":"2.0"},{"groupId":"OG001","spread":"19.60","value":"1.4"}]}],"title":"Diarrhoea"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.28","value":"0.2"},{"groupId":"OG001","spread":"19.21","value":"0.1"}]}],"title":"Financial difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"543"},{"groupId":"OG001","value":"257"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 core measurement was used to capture distal outcomes, including physical, social functioning, and overall health-related quality of life. The questionnaire incorporates 30 questions comprising nine multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality of life scale. All raw domain scores are linearly transformed to a 0-100 scale. All domains except for the global health and quality are presented. An increase in activity or functioning scores indicates improvement (higher/healthier level of functioning) and a decrease in symptom scores indicates improvement (lower level of symptoms/problems).","dispersionType":"Standard Deviation","groups":[{"description":"Relugolix 120-mg tablet administered orally once daily for 48 weeks following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1.","id":"OG000","title":"Relugolix"},{"description":"Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan), every 3 months by subcutaneous injection.","id":"OG001","title":"Leuprolide Acetate"}],"paramType":"MEAN","populationDescription":"All randomized participants who received at least 1 dose of study drug and had analyzable data at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 49 Day 1 (Day 337)","title":"Change From Baseline In QoL Total Score For Remaining Domain Scores As Assessed By The EORTC-QLQ-C30","type":"SECONDARY","unitOfMeasure":"score on a scale"}